2-(4-(tert-Butoxycarbonyl)-2-oxopiperazin-1-yl)acetic acid

Catalog No.: 
ACMCTB058
CAS No.: 
549506-47-0
Molecular Formula: 
C11H18N2O5
Molecular Weight: 
258.27
2-(4-(tert-Butoxycarbonyl)-2-oxopiperazin-1-yl)acetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g98%$138.00In stockInquiry
25g98%$688.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(4-(tert-Butoxycarbonyl)-2-oxopiperazin-1-yl)acetic acid
IUPAC Name2-(4-(tert-butoxycarbonyl)-2-oxopiperazin-1-yl)acetic acid
MDL No.MFCD04115297
Molecular FormulaC11H18N2O5
Molecular Weight258.27
SMILESCC(C)(C)OC(=O)N1CCN(CC(O)=O)C(=O)C1
InChI KeyQHPTYSXSHRLTHM-UHFFFAOYSA-N
Synonym549506-47-0 | 4-N-Boc-2-oxo-piperazine-1-acetic acid | 2-oxo-4-boc-1-piperazineacetic acid | 2-(4-(tert-butoxycarbonyl)-2-oxopiperazin-1-yl)acetic acid | 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]-2-oxopiperazin-1-yl]acetic acid | 4-boc-1-carboxymethylpiperazin-2-one |
CAS No.549506-47-0
PubChem CID17040175

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACMCTB058 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMCTB058 route product structure diagram
    ACMCTB058549506-47-0In Stock
Inquiry

2. ACMCTB058 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMCTB058 route product structure diagram
    ACMCTB058549506-47-0In Stock
Inquiry

3. ACMCTB058 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMCTB058 route product structure diagram
    ACMCTB058549506-47-0In Stock
Inquiry

Comments (0)